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Perspective: The study confirms that the recurrence rate of
AF/AT late after RFCA of AF is 5-10%/year. Delayed recon-
nection of the PVs probably is the major reason for late
recurrence of AF/AT in patients with paroxysmal AF. In
patients with persistent AF, contributing factors include PV
reconnection, ongoing left atrial remodeling, and underlying
comorbidities such as obesity, sleep apnea, and hypertension.
Summary written by: Fred Morady, MD
Cost-Effectiveness of Dabigatran Etexilate for the
Prevention of Stroke and Systemic Embolism in UK
Patients With Atrial Fibrillation
Kansal AR, Sorensen SV, Gani R, et al.
Heart 2012;98:573-578.
Study Question: How cost-effective is dabigatran compared to
warfarin, aspirin, or no therapy in patients with atrial fibrilla-
tion (AF)? 
Methods: The cost-effectiveness of dabigatran was deter-
mined using a Markov model. The dabigatran dose used
was 150 mg twice daily until age 80, then 110 mg twice
daily. In the warfarin group, the international normalized
ratio was assumed to be in therapeutic range (2-3) 64% of
the time, consistent with trial data. Estimates of major clini-
cal events were based on data from published trials and
meta-analyses. Cost-effectiveness was expressed as incre-
mental cost per quality-adjusted year of life (QALY) gained. 
Results: The increase in QALYs was higher with dabigatran
(8.06) than warfarin (7.82). The lifetime cost per patient for
disease management also was higher with dabigatran
(£19,645) than warfarin (£18,474). Aspirin provided 7.59
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Arrhythmias
Six Year Follow-Up After Catheter Ablation of Atrial
Fibrillation: A Palliation More Than a True Cure
Sorgente A, Tung P, Wylie J, Josephson ME
Am J Cardiol 2012;109:1179-1186.
Study Question: What are the long-term results of radiofre-
quency catheter ablation (RFCA) of atrial fibrillation (AF)? 
Methods: In this retrospective study, 103 patients (mean age
53 years) underwent RFCA of AF (nonparoxysmal in 61%)
and were followed for ≥4 years (median follow-up 6 years).
All patients underwent pulmonary vein (PV) isolation.
Additional ablation was performed at the operator’s discre-
tion if AF or atrial tachycardia (AT) was inducible by rapid
pacing. Long-term follow-up consisted of periodic Holter or
continuous loop monitoring and clinic visit at least once a
year. 
Results: AF/AT recurred in 80/103 patients after the first
procedure. A second procedure was performed in 42 and a
third in 7 patients. The incidence of freedom from AF/AT
was 63% at 1 year, 53% at 2 years, 45% at 4 years, and
39%at 6 years. The strongest predictor of recurrent AF/AT
was nonparoxysmal AF. There was freedom from AF/AT at
6 years in 50% of patients with paroxysmal compared to
31% with nonparoxysmal AF. 
Conclusions: In approximately two-thirds of patients with
recurrent AF/AT after RFCA of AF, the arrhythmia recurs
during the first year of follow-up. AF/AT continues to recur
during subsequent years of follow-up. 
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Perspective: TAVR is one of the most important advances in
treatment of valve disease, and this study demonstrates the
durability of the results of this technique. Aortic regurgitation
was more commonly seen with TAVR and was associated
with an increased risk of death. The results of this study
reflect early experience with the first-generation device, and it
is likely that ongoing refinement in technique and newer gen-
eration devices will be associated with further improvement in
procedural results and long-term outcomes.
Summary written by: Debabrata Mukherjee, MD
Comparison of Long-Term Survival After Open vs
Endovascular Repair of Intact Abdominal Aortic
Aneurysm Among Medicare Beneficiaries
Jackson RS, Chang DC, Freischlag JA.
JAMA 2012;307:1621-1628.
Study Question: What are the long-term outcomes after open
versus endovascular repair of abdominal aortic aneurysm
(AAA)? 
Methods: This was a retrospective analysis of patients 65 years
or older in the Medicare Standard Analytic File, 2003-2007,
who underwent isolated repair of intact AAA. Cause of
death was determined from the National Death Index. The
primary outcome measure was all-cause mortality. Secondary
outcomes were AAA-related mortality, hospital length of
stay, 1-year readmission, repeat AAA repair, incisional her-
nia repair, and lower extremity amputation. 
Results: Of 4,529 included patients, 703 were classified as
having undergone open repair and 3,826  endovascular
repair. Mean and median follow-up times were 2.6 and 2.5
years, respectively. Both all-cause mortality (173 vs. 752)
and AAA-specific mortality (22 vs. 28) were higher after
open versus endovascular repair. After adjusting for emer-
gency admission, age, calendar year, sex, race, and
comorbidities, there was a higher risk of both all-cause mor-
tality (hazard ratio [HR], 1.24) and AAA-related mortality
(HR, 4.37) after open versus endovascular repair. The
adjusted hospital length of stay was, on average, 6.5 days
longer after open repair (mean, 10.4 days), compared with
endovascular repair (mean, 3.6 days). Incidence of incisional
hernia repair was higher after open AAA repair (19 vs. 23),
whereas the incidence of 1-year readmission (188 vs. 1,070),
repeat AAA repair (15 vs. 93), and lower extremity amputa-
tion (3 vs. 25) did not differ by repair type. 
Conclusions: Among older patients with isolated intact AAA,
use of open repair compared with endovascular repair was
associated with increased risk of all-cause mortality and
AAA-related mortality.
Perspective: This study reports a long-term overall and AAA-
specific survival advantage associated with endovascular repair
of intact AAA, compared with open repair, which persisted in
multivariable analysis. Furthermore, there was no evidence of
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QALYs and was associated with a management cost of
£18,561. The largest management cost (£20,475) was
incurred by no therapy. The incremental cost-effectiveness
ratio (ICER) of dabigatran compared to warfarin was
£4,831/QALY gained in patients under age 80 and
£7,090/QALY gained over age of 80. Under the age of 80
years, the ICER of dabigatran compared to aspirin was
£3,457/QALY gained. Dabigatran was more effective and
less costly than no therapy.
Conclusions: Dabigatran is cost-effective in patients with AF. 
Perspective: The benchmark for acceptable cost-effectiveness is
£20,000/QALY gained. Therefore, the results of this study
suggest that the cost-effectiveness of dabigatran is quite rea-
sonable. The favorable cost-effectiveness of dabigatran despite
its higher cost is attributable to an anticipated reduction in
major adverse clinical events and in long-term disability from
catastrophic events.
Summary written by: Fred Morady, MD
Cardiovascular Surgery
Off-Pump or On-Pump Coronary-Artery Bypass
Grafting at 30 Days
Lamy A, Devereaux PJ, Prabhakaran D, et al., on behalf of the
CORONARY Investigators.
N Engl J Med 2012;366:1489-1497.
Study Question: What are the benefits and risks of performing
coronary artery bypass grafting (CABG) with use of a beat-
ing-heart technique (off-pump CABG), as compared with use
of cardiopulmonary bypass (on-pump CABG)? 
Methods: At 79 centers in 19 countries, the investigators ran-
domly assigned 4,752 patients in whom CABG was
planned to undergo the procedure off-pump or on-pump.
The first coprimary outcome was a composite of death, or
nonfatal stroke, myocardial infarction, or new renal failure
requiring dialysis at 30 days after randomization. 
Results: There was no significant difference in the rate of the
primary composite outcome between off-pump and on-
pump CABG (9.8% vs. 10.3%; hazard ratio for the
off-pump group, 0.95; p = 0.59) or in any of its individual
components. The use of off-pump CABG, as compared
with on-pump CABG, significantly reduced the rates of
blood-product transfusion (50.7% vs. 63.3%; relative risk
[RR], 0.80; p < 0.001), reoperation for perioperative bleed-
ing (1.4% vs. 2.4%; RR, 0.61; p = 0.02), acute kidney injury
(28.0% vs. 32.1%; RR, 0.87; p = 0.01), and respiratory com-
plications (5.9% vs. 7.5%; RR, 0.79; p = 0.03), but increased
the rate of early repeat revascularizations (0.7% vs. 0.2%;
hazard ratio, 4.01; p = 0.01). 
Conclusions: There was no difference in the 2-year outcome
of patients treated with TAVR or surgery for aortic stenosis.
Conclusions: Major and minor ECG abnormalities among older
adults were associated with an increased risk of CHD events. 
Perspective: Given the study results and the safety, low cost,
and wide availability of ECGs, ECG data might be useful
to improve CHD risk prediction in older adults. Given the
relatively small sample size and other limitations of the cur-
rent analysis including lack of good model calibration, the
benefits of ECG screening should be examined in prospec-
tive clinical trials prior to systematic screening in
asymptomatic populations.
Summary written by: Debabrata Mukherjee, MD
Effect of a Multifaceted Intervention on Use of
Evidence-Based Therapies in Patients With Acute
Coronary Syndromes in Brazil: The BRIDGE-ACS
Randomized Trial
Berwanger O, Guimarães HP, Laranjeira LN, et al., on behalf of
the BRIDGE-ACS Investigators.
JAMA 2012;Mar 25:[Epub ahead of print].
Study Question: What is the effect of a multifaceted quality
improvement (QI) intervention on the use of evidence-
based therapies and the incidence of major cardiovascular
events among patients with acute coronary syndrome (ACS)
in a middle-income country?
Methods: BRIDGE-ACS, a cluster-randomized trial, was
conducted among 34 clusters (public hospitals) in Brazil and
enrolled a total of 1,150 patients with ACS from March 15-
November 2, 2011, with follow-up through January 27,
2012. Multifaceted QI intervention including educational
materials for clinicians, reminders, algorithms, and case
manager training, versus routine practice (control) was con-
ducted. The primary endpoint was the percentage of eligible
patients who received all evidence-based therapies (aspirin,
clopidogrel, anticoagulants, and statins) during the first 24
hours in patients without contraindications. 
Results: Mean age of the patients enrolled was 62 years;
68.6% were men, and 40% presented with ST-segment ele-
vation myocardial infarction, 35.6% with non–ST-segment
elevation myocardial infarction, and 23.6% with unstable
angina. The randomized clusters included 79.5% teaching
hospitals, all from major urban areas, and 41.2% with 24-
hour percutaneous coronary intervention capabilities.
Among eligible patients (923), 67.9% in the intervention
versus 49.5% in the control group received all eligible acute
therapies. Similarly, among eligible patients (801), those in
the intervention group were more likely to receive all eligible
acute and discharge medications (50.9% vs. 31.9%). Overall
composite adherence scores were higher in the intervention
clusters (89% vs. 81.4%). In-hospital cardiovascular event
rates were 5.5% in the intervention group versus 7.0% in the
control group; 30-day all-cause mortality was 7.0% versus
8.4%. 
differences in the hazard of rehospitalization within 1 year
after AAA repair, repeat repair, or lower extremity amputa-
tion, making endovascular repair an attractive modality. Given
multiple limitations of this analysis, a randomized prospective
study would be needed to confirm the benefits of endovascular
repair.
Summary written by: Debabrata Mukherjee, MD
General Cardiology
Association of Major and Minor ECG Abnormalities
With Coronary Heart Disease Events
Auer R, Bauer DC, Marques-Vidal P, et al., on behalf of the
Health ABC Study.
JAMA 2012;307:1497-1505.
Study Question: What is the association between baseline elec-
trocardiogram (ECG) abnormalities or development of new
and persistent ECG abnormalities with increased coronary
heart disease (CHD) events? 
Methods: This was a population-based study of 2,192 white
and black older adults ages 70-79 years from the Health,
Aging, and Body Composition Study without known car-
diovascular disease. Adjudicated CHD events were collected
over 8 years between 1997-1998 and 2006-2007. Baseline
and 4-year ECG abnormalities were classified according to
the Minnesota Code as major and minor. Using Cox pro-
portional hazards regression models, the addition of ECG
abnormalities to traditional risk factors was examined to pre-
dict CHD events. The main outcome measures were the
adjudicated CHD events (acute myocardial infarction [MI],
CHD death, and hospitalization for angina or coronary
revascularization). 
Results: At baseline, 276 participants had minor and 506
had major ECG abnormalities. During follow-up, 351 par-
ticipants had CHD events (96 CHD deaths, 101 acute
MIs, and 154 hospitalizations for angina or coronary revas-
cularizations). Both baseline minor and major ECG
abnormalities were associated with an increased risk of
CHD after adjustment for traditional risk factors (17.2 per
1,000 person-years among those with no abnormalities;
29.3 per 1,000 person-years for minor abnormalities; and
31.6 per 1,000 person-years for major abnormalities). When
ECG abnormalities were added to a model containing tra-
ditional risk factors alone, 13.6% of intermediate-risk
participants with major and minor ECG abnormalities were
correctly reclassified (overall net reclassification improve-
ment [NRI], 7.4%). After 4 years, 208 participants had new
and 416 had persistent abnormalities; both were associated
with an increased risk of subsequent CHD events. When
added to the Framingham Risk Score, the NRI was not sig-
nificant (5.7%). 
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Conclusions: A multifaceted educational intervention resulted
in significant improvement in the use of evidence-based
therapies.
Perspective: In this trial, a multifaceted QI intervention was
effective in improving quality of ACS care in public hospi-
tals. The intervention increased the uptake of evidence-
based therapies during the first 24 hours, mainly driven by
increased prescription rates of antithrombotic therapies and
statins. However, the study was not powered for the evalu-
ation of clinical outcomes, and the low number of events
and wide confidence intervals make interpretation of the
clinical endpoint results inconclusive. Larger studies with
adequate power are warranted to assess the effect of QI
interventions on clinical outcomes and cost-effectiveness.
Summary written by: Debabrata Mukherjee, MD
Out-of-Hospital Administration of Intravenous
Glucose-Insulin-Potassium in Patients With
Suspected Acute Coronary Syndromes:
The IMMEDIATE Randomized Controlled Trial
Selker HP, Beshansky JR, Sheehan PR, et al.
JAMA 2012;Mar 27:[Epub ahead of print].
Study Question: What is the impact of out-of-hospital emer-
gency medical service (EMS) administration of
glucose-insulin-potassium (GIK) in the first hours of sus-
pected acute coronary syndromes (ACS)? 
Methods: IMMEDIATE was a randomized, placebo-con-
trolled, double-blind effectiveness trial in 13 US cities (36
EMS agencies), from December 2006-July 31, 2011, in
which paramedics, aided by electrocardiogram (ECG)-based
decision support, randomized 911 (871 enrolled) patients
(mean age, 63.6 years; 71.0% men) with high probability of
ACS. Intravenous GIK solution (n = 411) or identical-
appearing 5% glucose placebo (n = 460) was administered
by paramedics in the out-of-hospital setting and continued
for 12 hours. The prespecified primary endpoint was pro-
gression of ACS to myocardial infarction (MI) within 24
hours, as assessed by biomarkers and ECG evidence.
Prespecified secondary endpoints included survival at 30
days and a composite of prehospital or in-hospital cardiac
arrest or in-hospital mortality, analyzed by intent-to-treat
and presentation with ST-segment elevation.
Results: There was no significant difference in the rate of
progression to MI among patients who received GIK (n =
200; 48.7%) versus placebo (n = 242; 52.6%; p = 0.28).
Thirty-day mortality was 4.4% with GIK versus 6.1% with
placebo (p = 0.27). The composite of cardiac arrest or in-
hospital mortality occurred in 4.4% with GIK versus 8.7%
with placebo (p = 0.01). Among patients with ST-segment
elevation (163 with GIK and 194 with placebo), progres-
sion to MI was 85.3% with GIK versus 88.7% with placebo
(p = 0.34); 30-day mortality was 4.9% with GIK versus
7.7% with placebo (p = 0.29). The composite outcome of
cardiac arrest or in-hospital mortality was 6.1% with GIK
versus 14.4% with placebo (p = 0.01). Serious adverse events
occurred in 6.8% (n = 28) with GIK versus 8.9% (n = 41)
with placebo (p = 0.26).
Conclusions: Among patients with suspected ACS, out-of-hos-
pital administration of intravenous GIK, compared with
glucose placebo, did not reduce progression to MI. 
Perspective: In the IMMEDIATE trial, compared with
placebo, GIK administration was also not associated with
improvement in 30-day survival, but was associated with
lower rates of the composite outcome of cardiac arrest or in-
hospital mortality. While additional studies with longer
follow-up are needed to assess the out-of-hospital use of
GIK as therapy for patients with ACS, the clinical utility
remains uncertain.
Summary written by: Debabrata Mukherjee, MD
Intracoronary Abciximab and Aspiration
Thrombectomy in Patients With Large
Anterior Myocardial Infarction:
The INFUSE-AMI Randomized Trial
Stone GW, Maehara A, Witzenbichler B, et al., on behalf of the
INFUSE-AMI Investigators.
JAMA 2012;Mar 25:[Epub ahead of print].
Study Question: What is the impact of intracoronary abciximab,
aspiration thrombectomy, or both on infarct size in patients
with ST-segment elevation myocardial infarction (STEMI)? 
Methods: The authors performed a randomized trial of 452
patients presenting within 4 hours of STEMI due to proxi-
mal or mid left anterior descending artery occlusion
undergoing primary PCI with bivalirudin anticoagulation.
Patients were randomized in an open-label, 2 x 2 factorial
design to bolus intracoronary abciximab delivered locally at
the infarct lesion site versus no abciximab, and to manual
aspiration thrombectomy versus no thrombectomy. The pri-
mary endpoint was infarct size at 30 days assessed by cardiac
magnetic resonance imaging in the abciximab versus no
abciximab groups (pooled across the aspiration randomiza-
tion) and the major secondary endpoint was 30-day infarct
size in the aspiration versus no aspiration groups (pooled
across the abciximab randomization).
Results: Patients randomized to intracoronary abciximab had
a significant reduction in 30-day infarct size (median, 15.1%
vs. 17.9%; p = 0.03) and a significant reduction in absolute
infarct mass (median 18.7 g vs. 24.0 g; p = 0.03), but there
was no difference in the abnormal wall motion score
(median, 7.0 vs. 8.0; p = 0.08). Patients randomized to aspi-
ration thrombectomy versus no aspiration had no significant
difference in infarct size at 30 days (median, 17.0% vs.
17.3%; p = 0.51), absolute infarct mass (median, 20.3 g vs.
21.0 g; p = 0.36), or abnormal wall motion score. 
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Results: Of 153 patients who provided consent, a total of 92
(82 men; average age: 63 years) were randomized (n = 61 in
the BMC group and n = 31 in the placebo group). Changes
in LVESV index (−0.9 ml/m2; 95% confidence interval [CI],
−6.1 to 4.3; p = 0.73), maximal oxygen consumption (1.0;
95% CI, −0.42 to 2.34; p = 0.17), and reversible defect (−1.2;
95% CI, −12.50 to 10.12; p = 0.84) were not statistically sig-
nificant. There were no differences found in any of the
secondary outcomes, including percent myocardial defect,
total defect size, fixed defect size, regional wall motion, and
clinical improvement. 
Conclusions: Among patients with chronic ischemic heart fail-
ure, transendocardial injection of autologous BMCs compared
with placebo did not improve LVESV, maximal oxygen con-
sumption, or reversibility on SPECT.  
Perspective: This large, adequately powered study found no sig-
nificant differences in a priori selected primary endpoints
between patients treated with BMCs and placebo in this first-
in-man study. While further studies to determine the
relationship between the composition and function of bone
marrow product and clinical endpoints are indicated, the
future for cell therapy using current methodology does not
look promising.
Summary written by: Debabrata Mukherjee, MD
Interventional Cardiology
Outcomes of PCI at Hospitals With or Without
On-Site Cardiac Surgery
Aversano T, Lemmon CC, Liu L, on behalf of the
Atlantic C-PORT Investigators.
N Engl J Med 2012;Mar 25:[Epub ahead of print].
Study Question: What are the outcomes of percutaneous coro-
nary intervention (PCI) performed at hospitals without and
with on-site cardiac surgery? 
Methods: The investigators randomly assigned participants to
undergo PCI at a hospital with or without on-site cardiac
surgery. Patients requiring primary PCI were excluded. The
trial had two primary endpoints: 6-week mortality and 9-
month incidence of major adverse cardiac events (MACE)
(the composite of death, Q-wave myocardial infarction, or
target vessel revascularization). Noninferiority margins for
the risk difference were 0.4% for mortality at 6 weeks and
1.8% for MACE at 9 months. 
Results: A total of 18,867 patients were randomly assigned in
a 3:1 ratio to undergo PCI at a hospital without (14,149
patients) or with on-site cardiac surgery (4,718 patients).
The 6-week mortality rate was 0.9% at hospitals without ver-
sus 1.0% at those with on-site surgery (difference, −0.04
percentage points; p = 0.004 for noninferiority). The 9-
month rates of MACE were 12.1% and 11.2% at hospitals
Conclusions: In patients with anterior wall STEMI, intracoro-
nary abciximab was associated with a reduction in infarct size.  
Perspective: This study demonstrates a slight improvement in
myocardial salvage with intracoronary abciximab in patients
undergoing primary PCI, although the clinical impact of this
remains unclear. The recently published AIDA STEMI study
(Thiele H, et al. Lancet 2012;379:923-31) demonstrated a
slight reduction in congestive heart failure with intracoronary
abciximab, and given the results of these two studies, it would
be reasonable to consider an intracoronary route, if abciximab
use is contemplated. This study did not find any benefit of
aspiration thrombectomy, which is currently used in nearly a
third of patients undergoing primary PCI, and invokes the
need for large dedicated trials to assess the clinical effective-
ness of this common practice.
Summary written by: Hitinder S. Gurm, MBBS
Heart Failure/Transplant
Effect of Transendocardial Delivery of Autologous
Bone Marrow Mononuclear Cells on Functional
Capacity, Left Ventricular Function, and Perfusion
in Chronic Heart Failure: The FOCUS-CCTRN Trial
Perin EC, Willerson JT, Pepine CJ, et al., on behalf of the
Cardiovascular Cell Therapy Research Network (CCTRN).
JAMA 2012;Mar 24:[Epub ahead of print].
Study Question: What is the effect of bone marrow mononuclear
cell (BMC) administration through transendocardial injections
on myocardial perfusion, left ventricular end-systolic volume
(LVESV), and maximal oxygen consumption in patients with
coronary artery disease or LV dysfunction, and limiting heart
failure or angina? 
Methods: FOCUS-CCTRN was a phase 2 randomized, dou-
ble-blind, placebo-controlled trial of symptomatic patients
(New York Heart Association class II-III or Canadian
Cardiovascular Society class II-IV) with an LV ejection
fraction of 45% or less, a perfusion defect by single-photon
emission tomography (SPECT), and coronary artery disease
not amenable to revascularization, who were receiving maxi-
mal medical therapy at five National Heart, Lung, and
Blood Institute–sponsored Cardiovascular Cell Therapy
Research Network (CCTRN) sites between April 29, 2009,
and April 18, 2011. Bone marrow aspiration and transendo-
cardial injection of 100 million BMCs or placebo (ratio of 2
for BMC group to 1 for placebo) was performed. The main
outcome measures included co-primary endpoints assessed
at 6 months: changes in LVESV assessed by echocardiogra-
phy, maximal oxygen consumption, and reversibility on
SPECT. Phenotypic and functional analyses of the cell
product were performed by the CCTRN biorepository core
laboratory. 
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without and with on-site surgery, respectively (difference,
0.92 percentage points; p = 0.05 for noninferiority). The rate
of target vessel revascularization was higher in hospitals
without on-site surgery (6.5% vs. 5.4%, p = 0.01). 
Conclusions: PCI performed at hospitals without on-site car-
diac surgery was noninferior to PCI performed at hospitals
with on-site cardiac surgery. 
Perspective: This study suggests that for outcomes of PCI
at hospitals without to be similar to those at hospitals with
on-site cardiac surgery, it may be helpful for such centers
to participate in a formal PCI development program and
for interventionalists who perform the procedures to meet
the criteria for competency developed by the American
College of Cardiology/American Heart Association/Society
for Cardiovascular Angiography and Interventions.                                                           
Summary written by: Debabrata Mukherjee, MD
Clinical Outcomes Following Radial Versus Femoral
Artery Access in Primary or Rescue Percutaneous
Coronary Intervention in Scotland: Retrospective
Cohort Study of 4534 Patients
Johnman C, Pell JP, Mackay DF, et al.
Heart 2012;98:552-557.
Study Question: What are the short- and medium-term out-
comes following radial and femoral artery access for primary
or rescue percutaneous coronary intervention (PCI)? 
Methods: This was a Scotland-wide retrospective cohort
study of 4,534 patients undergoing primary or rescue PCI in
Scotland between April 2000 and March 2009 using the
Scottish Coronary Revascularization Register. Radial and
femoral artery access were based on the reported final access
site. The main outcome measures were procedural success;
periprocedural complications; 30-day and 1-year mortality,
myocardial infarction, or stroke; and long-term mortality.
Cox proportional-hazards regression was used to determine
the unadjusted and adjusted hazard ratio for survival in
radial versus femoral access patients, with radial access form-
ing the referent population. 
Results: Use of the radial approach increased from no cases
in 2000 to 924 (80.5%) in 2009 (p < 0.001). Radial
approach patients were more likely to be male (p = 0.041)
and have multiple comorbidities (p < 0.001), including
hypertension (p < 0.001) and left ventricular dysfunction (p
< 0.001). They were less likely to have renal impairment (p
= 0.017), multivessel coronary disease (p = 0.001), and car-
diogenic shock (p < 0.001). In multivariable analyses, use of
radial artery access was associated with greater procedural
success (p = 0.002) and a lower risk of any complications (p
= 0.001) or access site bleeding complications (p = 0.002), as
well as a lower risk of myocardial infarction (p = 0.003) or
death within 30 days (p < 0.001). The differences in
myocardial infarction and death remained significant up to 9
years of follow-up. 
Conclusions: The use of the radial artery for primary or rescue
PCI is associated with improved clinical outcomes. 
Perspective: This study reports that compared with femoral
access, primary and rescue PCI undertaken using radial access
had a higher rate of procedural success and a lower risk of
periprocedural, 30-day, and 1-year adverse events. A limita-
tion of this study was the lack of data regarding planned initial
access route, crossover rate, and inability to adjust for con-
founders. Additional randomized prospective studies are
indicated to further solidify the assertion that radial artery
access should be the most preferred initial approach.
Summary written by: Debabrata Mukherjee, MD
Two-Year Outcomes After Transcatheter or Surgical
Aortic-Valve Replacement
Kodali SK, Williams MR, Smith CR, et al., on behalf of the
PARTNER Trial Investigators.
N Engl J Med 2012;366:1686-1695.
Study Question: What is the relative safety and efficacy of
transcatheter or surgical aortic valve replacement at 2 years? 
Methods: The authors reported the 2-year results of the
PARTNER trial. This trial randomized 699 high-risk
patients with severe aortic stenosis to surgical aortic valve
replacement (surgical AVR) or transcatheter aortic valve
replacement (TAVR). 
Results: There was no difference in 2-year mortality (33.9%
with TAVR vs. 35% with surgery; p = 0.41) or frequency of
stroke (p = 0.52). Endocarditis was uncommon (1.5% vs.
1%) and improvement in valve area was maintained at 2
years in both arms. Paravalvular regurgitation was more
common with TAVR and was an independent predictor of
death on follow-up. 
Conclusions: There was no difference in the 2-year outcome
of patients treated with TAVR or surgery for aortic stenosis. 
Perspective: TAVR is one of the most important advances in
treatment of valve disease, and this study demonstrates the
durability of the results of this technique. Aortic regurgita-
tion was more commonly seen with TAVR and was
associated with an increased risk of death. The results of this
study reflect early experience with the first-generation
device, and it is likely that ongoing refinement in technique
and newer generation devices will be associated with further
improvement in procedural results and long-term outcomes.
Summary written by: Hitinder S. Gurm, MBBS
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CT Angiography for Safe Discharge of Patients
With Possible Acute Coronary Syndromes
Litt HL, Gatsonis C, Snyder B, et al.
N Engl J Med 2012;366:1393-1403.
Study Question: Does coronary computed tomographic angiog-
raphy (CCTA) in the emergency department allow safe early
discharge of patients presenting with chest pain?
Methods: Patients with possible acute coronary syndrome
presenting to one of five US centers thought to be at low to
intermediate risk were randomly assigned in a 2:1 ratio to
undergo or not undergo CCTA. Patients >30 years of age
with a TIMI (Thrombolysis in Myocardial Infarction) risk
score of 0-2 and signs or symptoms warranting admission or
testing were eligible. The primary outcome was safety,
assessed in the subgroup with a negative CCTA, and
defined as the absence of myocardial infarction and cardiac
death during the first 30 days after presentation.  
Results: A total of 1,370 subjects were enrolled (908 in the
CCTA group and 462 in the group receiving traditional
care). Baseline characteristics were similar in the two groups.
Of 640 patients with a negative CCTA examination, none
died or had a myocardial infarction within 30 days.
Compared to patients receiving traditional care, CCTA
patients had a higher rate of discharge from the emergency
department (49.6% vs. 22.7%), a shorter length of stay
(median 18.0 hours vs. 24.8 hours), and a higher rate of
detection of coronary disease (9.0% vs. 3.5%). There was
one serious adverse event in each group. 
Conclusions: A CCTA-based strategy for low- to intermedi-
ate-risk patients presenting with a possible acute coronary
syndrome appears to allow the safe, expedited discharge
from the emergency department of many patients who
would otherwise be admitted. 
Perspective: This large randomized study demonstrated that
there were fewer hospitalizations and shorter lengths of stay
when CCTA was routinely used among these patients.
Although revascularization rates were low in both groups, they
were higher among patients who underwent CCTA; it is
questionable whether revascularization lowered any present or
future risk. The long-term risks of radiation exposure with
CCTA were not assessed in this short-term study. CCTA
might provide an expedient means for disposition of low- to
intermediate-risk patients with chest pain, but there still
might be a role for good clinical judgment and selective
testing.
Summary written by: David S. Bach, MD
Prevention/Vascular
Bariatric Surgery Versus Intensive Medical Therapy
in Obese Patients With Diabetes
Schauer PR, Kashyap SR, Wolski K, et al.
N Engl J Med 2012;366:1567-1576.
Study Question: What is the relative value of bariatric surgery
compared to medical therapy for glycemic control in type 2
diabetes mellitus? 
Methods: STAMPEDE was a randomized controlled single-
center trial comparing the efficacy of intensive medical
therapy alone versus medical therapy plus Roux-en-Y gastric
bypass or sleeve gastrectomy in 150 obese patients with
uncontrolled type 2 diabetes. All patients were treated with
lipid-lowering and antihypertensive medications with target
systolic blood pressure ≤130 mm Hg, diastolic blood pres-
sure ≤80 mm Hg, and low-density lipoprotein cholesterol
≤100 mg/dl. The primary endpoint was the proportion of
patients with a glycated hemoglobin (HgbA1c) level of 6.0%
or less 12 months after treatment.
Results: The mean age was 49 years, 66% were women, 44%
in each group used insulin, average HgbA1c was 9.2%, and
mean body mass index (BMI) was 36 kg/m2. Of the 150
patients, 93% completed 12 months of follow-up. The pro-
portion of patients reaching an HgbA1c of <6.0% was 12%
in the medical-therapy versus 42% in the gastric-bypass
group and 37% in the sleeve gastrectomy group, with no
difference between surgical groups. Glycemic control
improved in all three groups, with a mean HgbA1c level of
7.5% in the medical-therapy, 6.4% in the gastric-bypass,
and 6.6% in the sleeve-gastrectomy group. Weight loss was
greater in the gastric-bypass and sleeve-gastrectomy (-29.4 ±
9.0 kg and -25.1 ± 8.5 kg, respectively) than in the medical-
therapy group (-5.4 ± 8.0 kg). Insulin use remained high at
38% in the medical-therapy group, but reduced to 4% in the
gastric-bypass and 8% in the sleeve-gastrectomy group.
Triglycerides were reduced by 14% with medical treatment
and >40% in both surgical groups. The use of drugs to lower
glucose, lipid, and blood pressure levels decreased signifi-
cantly after both surgical procedures, but increased in
patients receiving medical therapy only. The index for
homeostasis model assessment of insulin resistance
improved significantly after bariatric surgery. Four patients
underwent reoperation. There were no deaths or life-threat-
ening complications.  
Conclusions: In obese patients with uncontrolled type 2 dia-
betes, 12 months of medical therapy plus bariatric surgery
achieved glycemic control in significantly more patients than
medical therapy alone. Further study will be necessary to
assess the durability of these results. 
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Perspective: The study was designed with a 4-year follow-up,
but the 12-month benefits in glycemic, weight, and lipid con-
trol are very encouraging. The evidence accumulating on the
value of bariatric surgery is impressive. The time seems right
for a randomized trial comparing intense medical therapy with
bariatric surgery in obese diabetics with poor glycemic control
with cardiovascular event and mortality endpoints.
Summary written by: Melvyn Rubenfire, MD
Comparative Effectiveness of Revascularization
Strategies
Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al.
N Engl J Med 2012;366:1467-1476.
Study Question: What is the comparative efficacy of the stan-
dard dose of alteplase with two different doses of
tenecteplase? 
Methods: The investigators linked the American College of
Cardiology Foundation National Cardiovascular Data
Registry and the Society of Thoracic Surgeons Adult
Cardiac Surgery Database to claims data from the Centers
for Medicare and Medicaid Services for the years 2004-
2008. Outcomes were compared with the use of propensity
scores and inverse-probability-weighting adjustment to
reduce treatment selection bias. 
Results: Among patients ≥65 years old who had two- or
three-vessel coronary artery disease without acute myocardial
infarction, 86,244 underwent CABG and 103,549 under-
went PCI. The median follow-up was 2.67 years. At 1 year,
there was no significant difference in adjusted mortality
between the groups (6.24% in the CABG compared with
6.55% in the PCI group; risk ratio, 0.95). At 4 years, there
was lower mortality with CABG than PCI (16.4% vs.
20.8%; risk ratio, 0.79). Similar results were noted in multi-
ple subgroups and with the use of several analytic methods. 
Conclusions: Among older patients with multivessel coronary
disease, there was a long-term survival advantage among
patients who underwent CABG compared with patients who
underwent PCI. 
Perspective: In the context of the results of randomized trials,
a difference in mortality between PCI and CABG may be
expected among patients with complex disease, but was not
expected among patients with a lesser atherosclerotic burden.
Due to the observational nature of this study, differences in
unrecorded selection factors that relate to prognosis, rather
than an intrinsic mortality benefit from CABG, may explain
why the results in lower-risk patients in this study are not
consistent with the results from randomized trials.
Summary written by: Debabrata Mukherjee, MD
Vorapaxar in the Secondary Prevention of
Atherothrombotic Events
Morrow DA, Braunwald E, Bonaca MP et al., on behalf of the
TRA 2P–TIMI 50 Steering Committee and Investigators.
N Engl J Med 2012;Mar 24: [Epub ahead of print].
Study Question: What is the role of vorapaxar, a novel
antiplatelet agent that selectively inhibits the cellular actions
of thrombin through antagonism of protease-activated recep-
tor (PAR-1), for secondary prevention of atherothrombotic
events? 
Methods: The investigators randomly assigned 26,449
patients who had a history of myocardial infarction,
ischemic stroke, or peripheral arterial disease to receive
vorapaxar (2.5 mg daily) or matching placebo, and followed
them for a median of 30 months. The primary efficacy end-
point was the composite of death from cardiovascular
causes, myocardial infarction, or stroke. After 2 years, the
Data and Safety Monitoring Board recommended discon-
tinuation of the study treatment in patients with a history
of stroke, owing to the risk of intracranial hemorrhage. 
Results: At 3 years, the primary endpoint had occurred in
9.3% in the vorapaxar group and in 10.5% in the placebo
group (p < 0.001). Cardiovascular death, myocardial infarc-
tion, stroke, or recurrent ischemia leading to revasculari-
zation occurred in 11.2% in the vorapaxar group and 12.4%
with placebo (p = 0.001). Moderate or severe bleeding
occurred in 4.2% who received vorapaxar and 2.5% who
received placebo (p < 0.001). There was an increase in the
rate of intracranial hemorrhage in the vorapaxar group (p <
0.001). 
Conclusions: Vorapaxar reduced the risk of cardiovascular death
or ischemic events in patients with stable atherosclerosis who
were receiving standard therapy. 
Perspective: Although vorapaxar reduced the risk of cardiovas-
cular death or ischemic events in these study patients, it
increased the risk of moderate or severe bleeding, including
intracranial hemorrhage. Any clinical use of vorapaxar would
have to be based on an appropriate selection of patients, with
the risk of bleeding balanced against that of recurrent throm-
botic events, and the future role of this drug remains
uncertain.
Summary written by: Debabrata Mukherjee, MD
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